A Full Analysis of Eli Lilly ($LLY)

Together with Waldo

Hi everyone,

Happy Monday. We hope the weekend was kind and the coffee is doing its job, because today we are climbing into one of the most jaw-dropping growth stories in the entire market, and it happens to wear a lab coat instead of a hoodie.

Eli Lilly closed last week around $1,122 a share, sitting just below its all-time closing high of $1,160.95 set on June 11. The stock is up roughly 45% over the past twelve months, the kind of move you expect from a hot chip name, not a drugmaker that was founded in 1876. Let's get into why a 150-year-old company is suddenly growing like it just walked out of a startup accelerator.

Stock Deep Dive: Eli Lilly & Co. (LLY-US, $1T MCAP)

Lilly is the most valuable pharmaceutical company on the planet, and it earned that crown on the back of two molecules: Mounjaro for type 2 diabetes and Zepbound for obesity, both built on the same compound, tirzepatide. In 2025 those two drugs alone delivered roughly $36.5B in combined sales, about 56% of total revenue. The obesity wave is still in its early innings, and Lilly is surfing the very front of it.

The numbers are almost hard to believe. Full year 2025 revenue hit $65.18B, up 45% year over year, with net income of $20.64B. Then Q1 2026 somehow accelerated rather than cooled, posting $19.8B in revenue (up 56%) and pushing management to raise full year guidance to a range of $82B to $85B. Put differently, Lilly expects to add more revenue in a single year than many large-cap companies generate in total.

But the defining story for 2026 is the pill. In Q1 the FDA approved Foundayo (orforglipron), the first oral GLP-1 with no food or water restrictions, and that launch is the hinge on which the next decade swings. Below we break down how Lilly got here, how it actually makes its money, and where the cracks could form.

• Why Now 👉 the obesity gold rush has a clear frontrunner

• Overview 👉 a 150-year-old drugmaker reinvented by two molecules

• How Do They Win 👉 manufacturing muscle and an unmatched pipeline

• Business Units 👉 where the revenue actually comes from

• How Do They Make Money 👉 volume over price, on purpose

• By The Numbers 👉 software-style growth in a pharma body

• Bonus Deep Dive 👉 the pill war that decides the next decade

• Risks 👉 what could break the story

• Wrapping Up 👉 the bull and bear cases in one breath

👉 Maximize Yield on Company Cash Without Switching Banks

Most businesses leave millions in idle cash sitting in low-yield bank accounts earning next to nothing.

Waldo helps startups, SMBs, funds, and enterprises maximize yield on company cash through high-yield treasury accounts — all without requiring businesses to switch their existing bank.

Designed for modern finance teams, Waldo offers access to yields of 5%+ alongside SIPC insurance coverage up to $75M*, helping companies optimize treasury management while maintaining flexibility and security.

As interest rates remain elevated and capital efficiency becomes increasingly important, businesses are rethinking how they manage excess cash balances. Waldo aims to provide a simple, institutional-grade solution built for today’s operating environment.

Why Now 👉 the obesity gold rush has a clear frontrunner

The GLP-1 class of drugs has rewritten the map of modern medicine. What began as a diabetes treatment turned into the most commercially successful weight-loss therapy ever created, and analysts now throw around a total addressable market in the hundreds of billions of dollars. Lilly entered 2026 holding roughly 60% of the U.S. GLP-1 market, and it has been widening that gap rather than defending it.

The reason now matters so much is the shift from injections to pills. Injectable GLP-1s work, but they require refrigeration, needles, and supply chains that have historically buckled under runaway demand. An oral version that works nearly as well strips away the biggest barriers to mass adoption. Lilly's Foundayo cleared the FDA in Q1 2026 and went on sale in Q2, and early prescription data showed that 80% of new patients had never taken a GLP-1 before. That single detail is the whole ballgame: the pill is not stealing share, it is expanding the entire market.

Consider the runway. More than 100M American adults live with obesity, and a meaningful share of them have never tried a GLP-1 of any kind. The penetration rate is still low, the population is enormous, and a pill that can be shipped in a normal bottle to any pharmacy in the country is exactly the format that turns a high-end specialty drug into something closer to a mass consumer product. That is why the market reacts to every scrap of pill data, and why Lilly's lead here is worth so much more than its lead in injectables alone.

Overview 👉 a 150-year-old drugmaker reinvented by two molecules

Eli Lilly was founded in Indianapolis in 1876 and spent most of its long history as a respected but fairly ordinary pharma name, known over the decades for insulin, Prozac, and Cialis. The company reports as a single business segment, human pharmaceutical products, spanning cardiometabolic health, oncology, immunology, and neuroscience.

Then tirzepatide changed everything. Approved first as Mounjaro for type 2 diabetes and later as Zepbound for obesity, the compound hits two gut-hormone receptors (GIP and GLP-1) and delivered weight-loss results that stunned the field. That one molecule helped transform Lilly from a roughly $400B company a couple of years ago into one flirting with a $1T+ valuation. CEO David Ricks has leaned all the way in, pledging more than $27B in U.S. manufacturing build-out so that supply never caps the opportunity the way it did in late 2024.

What makes the story remarkable is how fast it happened. Lilly spent more than a century building a reputation on insulin, a product it commercialized in the 1920s, and on a string of well-known consumer drugs. Within just a few years, a single therapeutic area went from a promising line item to the majority of the company's revenue. Few businesses of this size have ever re-rated this quickly, and that speed is exactly what excites the bulls and unnerves the skeptics in equal measure.

How Do They Win 👉 manufacturing muscle and an unmatched pipeline

Two structural advantages separate Lilly from the pack. The first is manufacturing. GLP-1 drugs are notoriously hard to produce at scale, and the company that can make the most doses wins the most patients. Lilly has committed over $27B to U.S. capacity, including an additional $4.5B in Indiana announced in May, with new sites in Virginia, Texas, and an expanded footprint in Puerto Rico. As Ricks framed it, the goal is to build the most advanced plants in the world, not just to discover the medicines that fill them.

Subscribe to GritAlpha Premium to read the rest.